Literature DB >> 12728148

BTS guidelines for the management of malignant pleural effusions.

G Antunes1, E Neville, J Duffy, N Ali.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12728148      PMCID： PMC1766015          DOI： 10.1136/thorax.58.suppl_2.ii29

Source DB:  PubMed          Journal:  Thorax        ISSN： 0040-6376            Impact factor:   9.139


× No keyword cloud information.
  120 in total

1.  Corynebacterium parvum pleurodesis and survival is not significantly influenced by pleural pH and glucose level.

Authors:  S Bilaçeroğlu; U Cağirici; K Perim; R Ozacar
Journal:  Monaldi Arch Chest Dis       Date:  1998-02

2.  A randomized trial of intracavitary bleomycin and Corynebacterium parvum in the control of malignant pleural effusions.

Authors:  M J Ostrowski; T J Priestman; R F Houston; W M Martin
Journal:  Radiother Oncol       Date:  1989-01       Impact factor: 6.280

3.  Regional protein absorption rates from the pleural cavity in dogs.

Authors:  D Negrini; M Pistolesi; M Miniati; R Bellina; C Giuntini; G Miserocchi
Journal:  J Appl Physiol (1985)       Date:  1985-06

4.  Iodized talc pleurodesis for the treatment of pleural effusions.

Authors:  W R Webb; V Ozmen; P V Moulder; B Shabahang; J Breaux
Journal:  J Thorac Cardiovasc Surg       Date:  1992-05       Impact factor: 5.209

5.  [Intrapleural minocycline for postoperative air leakage and control of malignant pleural effusion].

Authors:  T Hatta; N Tsubota; M Yoshimura; M Yanagawa
Journal:  Kyobu Geka       Date:  1990-04

6.  A comparison of rotation and nonrotation in tetracycline pleurodesis.

Authors:  S R Dryzer; M L Allen; C Strange; S A Sahn
Journal:  Chest       Date:  1993-12       Impact factor: 9.410

7.  The cytologic diagnosis of malignant neoplasms in pleural and peritoneal effusions.

Authors:  D Sears; S I Hajdu
Journal:  Acta Cytol       Date:  1987 Mar-Apr       Impact factor: 2.319

8.  Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease.

Authors:  A Kraft; K Weindel; A Ochs; C Marth; J Zmija; P Schumacher; C Unger; D Marmé; G Gastl
Journal:  Cancer       Date:  1999-01-01       Impact factor: 6.860

9.  Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy.

Authors:  C Boutin; F Rey; J R Viallat
Journal:  Chest       Date:  1995-09       Impact factor: 9.410

10.  Intrapleural immunotherapy with escalating doses of interleukin-2 in metastatic pleural effusions.

Authors:  J R Viallat; C Boutin; F Rey; P Astoul; P Farisse; M Brandely
Journal:  Cancer       Date:  1993-06-15       Impact factor: 6.860
View more
  69 in total

1.  Management of traumatic hemothorax by closed thoracic drainage using a central venous catheter.

Authors:  Jian-hua Yi; Hua-bo Liu; Mao Zhang; Jun-song Wu; Jian-xin Yang; Jin-ming Chen; Shan-xiang Xu; Jian-an Wang
Journal:  J Zhejiang Univ Sci B       Date:  2012-01       Impact factor: 3.066

2.  BTS statement on malignant mesothelioma in the UK, 2007.

Authors: 
Journal:  Thorax       Date:  2007-11       Impact factor: 9.139

3.  Pleural Neutrophil-to-Lymphocyte Ratio May Be Associated With Early Disease Progression in Stage IV Non-small Cell Lung Cancer.

Authors:  Jeong Uk Lim; Chang Dong Yeo; Hyung Woo Kim; Hye Seon Kang; Chan Kwon Park; Ju Sang Kim; Jin Woo Kim; Seung Joon Kim; Sang Haak Lee
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

Review 4.  Minimally invasive palliative interventions in advanced lung cancer.

Authors:  Christopher Mallow; Margaret Hayes; Roy Semaan; Thomas Smith; Russell Hales; Roy Brower; Lonny Yarmus
Journal:  Expert Rev Respir Med       Date:  2018-06-19       Impact factor: 3.772

5.  Clinically important factors influencing the diagnostic measurement of pleural fluid pH and glucose.

Authors:  Najib M Rahman; Eleanor K Mishra; Helen E Davies; Robert J O Davies; Y C Gary Lee
Journal:  Am J Respir Crit Care Med       Date:  2008-06-12       Impact factor: 21.405

6.  A pilot study-is there a role for mitoxantrone pleurodesis in the management of pleural effusion due to lung cancer?

Authors:  Katherina-Bernadette Sreter; Marko Jakopovic; Zoran Janevski; Miroslav Samarzija; Paul Zarogoulidis; Ioannis Kioumis; Nikolaos Mparmpetakis; Athanasia Pataka; Konstantinos Zarogoulidis; Theodora Tsiouda; Christoforos Kosmidis; Sofia Mpaka; Haidong Huang; Wolfgang Hohenforst-Schmidt; Charalampos Charalampidis; Nikolaos Machairiotis; Bojan Zaric; Aleksandar Milovancev
Journal:  Ann Transl Med       Date:  2016-05

7.  Sodium hydroxide as a sclerosing agent in patients with neoplastic pleural effusion non-candidates for VATS: results of a minimally invasive protocol.

Authors:  Micaela Raices; Matías E Czerwonko; Agustin Dietrich; Alejandro Da Lozzo; Enrique Beveraggi; David Smith
Journal:  Updates Surg       Date:  2017-08-31

8.  Quality Gaps and Comparative Effectiveness of Management Strategies for Recurrent Malignant Pleural Effusions.

Authors:  David E Ost; Jiangong Niu; Hui Zhao; Horiana B Grosu; Sharon H Giordano
Journal:  Chest       Date:  2017-08-31       Impact factor: 9.410

9.  Increased pleural fluid adenosine deaminase levels in patients with malignant pleural effusions: a potential predictor of talc pleurodesis outcome.

Authors:  Huseyin Yildirim; Muzaffer Metintas; Güntülü Ak; Sinan Erginel; Fusun Alatas; Emel Kurt; Selma Metintas; Irfan Ucgun
Journal:  Lung       Date:  2007-10-19       Impact factor: 2.584

10.  Specific effects of bortezomib against experimental malignant pleural effusion: a preclinical study.

Authors:  Ioannis Psallidas; Sophia P Karabela; Charalampos Moschos; Taylor P Sherrill; Androniki Kollintza; Sophia Magkouta; Panagiota Theodoropoulou; Charis Roussos; Timothy S Blackwell; Ioannis Kalomenidis; Georgios T Stathopoulos
Journal:  Mol Cancer       Date:  2010-03-10       Impact factor: 27.401
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.